OakChart

Curis Inc

CRISHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.5915-0.0615 (-9.42%)
2026-11-12 05:20 CET
Market cap
3.95 USD m
Revenue, TTM
4.31 USD m
Net income, TTM
-21.15 USD m
Free cash flow, TTM
-30.59 USD m
EPS diluted, TTM
-14.29
P/E
-
Compare

Price

CRIS against its 20, 50 and 200-day averages
2050200beatmissearnings
0.0010.0020.0081.8M163.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRISclose 0.5920-day 0.5750-day 0.80200-day 8.320.59

97.9% under the 52-week high of 28.40 on 5 Dec 2025. 52-week low 0.33 on 16 Oct 2026. Last 15 sessions, 340.8% high to low

Volume 0.13× normal · the line is the 50-bar volume average

Profile

CRIS
52-week range, 1% of the way up
0.3228.40

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Employees24
IPOAug 01, 2000
Beta3.21
ATR, 14d0.21
Rel volume0.13
Short float18.58%
Insider own17.07%
Inst own10.20%

Snapshot

6 groups

Valuation

Index-
Market Cap3.95M
Enterprise Value-0.63M
Income-21.15M
Sales4.31M
Book/sh2.41
Cash/sh0.84
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees24
IPOAug 01, 2000

Ratios

P/E-
Forward P/E-
PEG-
P/S0.92
P/B0.25
P/C0.70
P/FCF-
EV/EBITDA-
EV/Sales-0.15
Quick Ratio0.49
Current Ratio0.49
Debt/Eq0.22
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-14.29
EPS next Y-5.03
EPS next Q-2.01
EPS this Y-180.00%
EPS next Y84.53%
EPS next 5Y6.87%
EPS past 3/5Y63.80% 45.78%
Sales past 3/5Y-2.42% -2.71%
EPS Y/Y TTM85.37%
Sales Y/Y TTM-62.17%
EPS Q/Q70.48%
Sales Q/Q-100.00%
EarningsNov 12 AMC
EPS/Sales Surpr.40.38% -100.00%

Ownership

Insider Own17.07%
Insider Trans0.00%
Inst Own10.20%
Inst Trans-3.35%
ROA-87.76%
ROE-693.93%
ROIC-450.54%
Gross Margin97.71%
Oper. Margin-833.40%
Profit Margin-490.33%
SMA203.36%
SMA50-26.15%
SMA200-92.89%
Trades-

Technical

Shs Outstand6.68M
Shs Float5.54M
Short Float18.58%
Short Ratio0.26
Short Interest1.03M
52W High28.40 -97.92%
52W Low0.32 82.00%
Volatility25.04% 29.19%
ATR (14)0.21
RSI (14)44.18
Beta3.21
Rel Volume0.13
Avg Volume3.94M
Volume513,144

Performance

Perf Week-46.71%
Perf Month-3.81%
Perf Quarter-68.37%
Perf Half Y-94.09%
Perf YTD-97.00%
Perf Year-97.63%
Perf 3Y-99.52%
Perf 5Y-99.98%
Perf 10Y-99.99%
Recom1.00
Target Price42.67
Prev Close0.65
Price0.59
Change %-9.42%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 19, 2025ResumedHH.C. WainwrightBuy$17+2,774.0%
Nov 17, 2023InitiatedTTruistBuy$26+4,295.6%
Apr 04, 2022DowngradeRRaymond JamesOutperform → Mkt Perform
Oct 13, 2021InitiatedRRaymond JamesOutperform$15+2,435.9%
Mar 25, 2021InitiatedRB. Riley SecuritiesBuy$19+3,112.2%
Jul 29, 2020InitiatedLLaidlawBuy$5+745.3%
Jul 17, 2020InitiatedCCantor FitzgeraldOverweight$4+576.2%
Oct 24, 2017InitiatedGGuggenheimBuy$7+1,083.4%
Mar 02, 2016InitiatedSSun Trust Rbsn HumphreyBuy$3+407.2%
Nov 09, 2015ReiteratedRROTH CapitalBuy$6 → $5+745.3%

Peers

Mkt cap
TickerCompanyMkt cap
KPTIKaryopharm Therapeutics Inc0.39M
KURAKura Oncology Inc687.66M
ATNMActinium Pharmaceuticals Inc49.99M
CRDFCardiff Oncology Inc59.54M
APREAprea Therapeutics Inc6.30M
PRLDPrelude Therapeutics Inc301.66M
ACRVAcrivon Therapeutics Inc67.28M
TPSTTempest Therapeutics Inc7.94M
GTBPGT Biopharma Inc8.14M
BYSIBeyondSpring Inc26.48M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
KAITIN KENNETH IDirectorMar 31 '26Buy0.5510,0005,48711,407Apr 01 07:51 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Curis Heads Into Third-Quarter Report With Its Balance Sheet, Not Its Loss, Under The Microscope (Earnings Whispers) +6.65% -23.04%
  • Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026 (PR Newswire) -23.42%
  • Curis Shares Surge 70.7% as Reverse Stock Split Vote and Upcoming Clinical Data Attract Investors (InvestorsHub) +55.48%
  • Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors (PR Newswire) -19.86%
  • Curis: Q2 Earnings Snapshot (Associated Press)
  • Curis, Inc. Announces Pricing of $5.6 Million Public Offering (PR Newswire) +11.98%
  • Curis Doses First Five Patients in TakeAim CLL Study (PR Newswire)
  • Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) (InvestorsHub)
  • Curis Announces Positive Emavusertib Update (PR Newswire)
  • Curis Consents First Six Patients in TakeAim CLL Study (PR Newswire) -14.31%
  • Curis opens 11 sites for emavusertib combo in TakeAim CLL trial (Clinical Trials Arena) +37.69%
  • Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split (PR Newswire) +55.98%
  • Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ... (GuruFocus.com) -9.16%
  • Curis: Q1 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--2.010--0.002
2026Q22026-07-30-4.147-6.955-4.1470.001.004
2026Q12026-05-12-25.000-6.533-25.0000.001.693
2025Q42026-03-1924.600-8.72024.5841.143.255
2025Q32025-11-06-9.800-11.560-9.8583.182.865
2025Q22025-08-05-13.600-27.200-13.6102.752.645
2025Q12025-05-06-25.000-22.120-24.9972.382.655
2024Q42025-03-31-25.000-26.800-25.0763.352.214
2024Q32024-11-14-34.000-36.600-33.9752.932.275
2024Q22024-08-01-40.600-35.866-40.5712.552.066
2024Q12024-05-07-41.000-40.834-41.0682.092.006
2023Q42024-02-08-40.600-42.334-40.5812.703.026
2023Q32023-11-02-42.600-46.520-42.5852.832.545
2023Q22023-08-03-48.000-47.200-49.4842.202.475
2023Q12023-05-04-48.000-40.800-47.8562.302.485
2022Q42023-03-13-48.000-52.000-46.9962.893.195

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-388--387.4710.00-
2020FY-244-234-245.810.8410.70
2021FY-200-190.67-198.4810.6510.66
2022FY-244-248.8-242.7310.1610.40
2023FY-179.2-176.3-179.1410.0210.30
2024FY-137.6-138.55-137.6110.919.87
2025FY-11.600-50.400-11.6009.4411.49
2026FY--32.480--0.00
2027FY--5.025--0.00
2028FY--9.370--5.29
2029FY-33.600--117
2030FY-49.800--149

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-051000.000.000.00
2026Q3S2026-08-212000.000.000.00
2026Q3S2026-07-303001.000.003.00
2026Q3S2026-07-273001.000.003.00
2026Q3S2026-06-303011.000.003.00
2026Q3S2026-05-133021.000.003.00
2026Q3S2026-03-202003.103.003.20
2026Q3S2026-01-242003.453.203.70
2026Q3S2025-11-112103.453.203.70
2026Q3S2025-11-102103.453.203.70
2026Q3S2025-11-091003.403.403.40
2026Q3S2025-11-081003.403.403.40
2026Q3S2025-11-071003.403.403.40
2026Q3S2025-11-061003.403.403.40

Estimate history

EPS, annual-3575.12-393.436-387.468-245.8-198.476-242.728-179.144-137.606-11.519-14.2866
Period201720182019202020212022202320242025TTM
EPS, quarterly-40.571-33.975-25.076-24.997-13.61-9.85824.584-24.994-4.017
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual9.89810.42810.00410.83510.64910.16210.02310.9089.4434.31
Period201720182019202020212022202320242025TTM
Sales, quarterly2.5462.9313.3452.382.7493.1761.13800
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0160.0830.0830.2290.2290.2420.2950.4240.6461.949
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.2950.3010.4240.5230.5350.6370.6461.9991.949
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.319.4410.9110.0210.1610.6510.8410.0010.43
Cost of Goods Sold Incl. D&A0.100.210.300.471.651.520.680.630.74
Gross Profit4.219.2310.619.568.519.1310.169.389.69
Selling, General and Administrative Excl. Other40.1742.1354.5557.8961.5351.2035.0533.7339.02
Research and Development25.4228.2538.5639.5043.2834.5222.9222.1824.41
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-35.95-32.90-43.94-48.33-53.02-42.06-24.90-24.36-29.33
Interest Expense1.202.190.612.024.774.475.094.853.93
Unusual Expense-15.73-27.190.600.000.000.000.003.50-
Net Income Before Taxes-21.15-7.58-43.39-47.41-56.67-45.44-29.91-32.14-32.58
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-21.15-7.58-43.39-47.41-56.67-45.44-29.91-32.14-32.58
Net Income From Continuing Operations-21.15-7.58-43.39-47.41-56.67-45.44-29.91-32.14-32.58
Net Income-21.15-7.58-43.39-47.41-56.67-45.44-29.91-32.14-32.58
EPS (Recurring)-15.06-40.43-136.27-179.14-242.73-198.48-245.80-357.98-393.44
EPS (Basic, Before Extraordinaries)-14.29-11.52-137.61-179.14-242.73-198.48-245.80-387.47-393.44
EPS (Diluted)-14.29-11.52-137.61-179.14-242.73-198.48-245.80-387.47-393.44
EBITDA-35.87-32.73-43.74-48.08-51.63-41.08-24.58-24.23-29.16
Non-Operating Income (Expense)0.270.321.772.941.121.100.090.560.68
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.864.025.936.006.755.282.702.663.94
Price To Sales Ratio5.171.381.776.735.0540.9336.795.642.19
Gross Margin97.7197.7397.2495.3483.7885.7493.7493.7292.90
Operating Margin-833.40-348.43-402.84-482.21-521.75-395.01-229.79-243.46-281.29
Net Margin-490.33-80.29-397.77-473.04-557.69-426.67-276.03-321.28-312.38
Shares Outstanding1.950.650.420.290.240.230.230.080.08
Market Capitalization3.953.9525.9775.0453.02436.23749.4156.5122.87

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.001.143.182.752.383.352.93
Cost of Goods Sold Incl. D&A0.010.010.040.050.060.070.030.08
Gross Profit-0.01-0.011.103.132.692.313.312.85
Selling, General and Administrative Excl. Other9.9311.518.6710.0510.9412.4612.3113.41
Research and Development6.716.455.836.437.468.548.979.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.94-11.52-7.57-6.92-8.25-10.16-8.99-10.57
Interest Expense0.000.000.310.890.430.550.85-
Unusual Expense-1.3012.76-27.190.000.000.000.000.00
Net Income Before Taxes-8.58-24.2019.36-7.73-8.59-10.62-9.62-10.09
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.58-24.2019.36-7.73-8.59-10.62-9.62-10.09
Net Income From Continuing Operations-8.58-24.2019.36-7.73-8.59-10.62-9.62-10.09
Net Income-8.58-24.2019.36-7.73-8.59-10.62-9.62-10.09
EPS (Recurring)-4.44-15.770.41-9.86-13.61-25.00-25.08-33.97
EPS (Basic, Before Extraordinaries)-4.02-24.9924.58-9.86-13.61-25.00-25.08-33.97
EPS (Diluted)-4.02-24.9924.58-9.86-13.61-25.00-25.08-33.97
EBITDA-9.93-11.51-7.53-6.89-8.21-10.10-8.98-10.51
Non-Operating Income (Expense)0.060.080.050.080.090.090.230.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.570.570.800.921.141.161.281.38
Price To Sales Ratio5.171.501.652.232.571.592.153.12
Gross Margin--96.8498.5297.8996.9399.0197.17
Operating Margin---665.20-218.01-300.15-426.76-268.88-360.53
Net Margin--1,700.88-243.36-312.59-446.05-287.53-344.32
Shares Outstanding1.952.000.650.640.540.520.420.30
Market Capitalization3.9521.8812.7621.1424.8421.9725.9732.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.0620.0056.3385.62115.88168.4920.7024.2760.23
Short Term Receivables0.003.352.792.983.223.043.242.863.07
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.853.041.783.523.271.221.060.830.99
Total Current Assets6.9226.3960.9192.12122.38172.7525.0027.9664.29
Net Property, Plant & Equipment1.953.393.495.096.257.240.300.270.37
Total Investments and Advances0.540.540.540.6424.6915.380.820.150.15
Intangible Assets8.988.988.988.988.988.988.988.988.98
Deferred Tax Assets0.510.860.841.201.561.790.04--
Other Assets1.571.963.362.020.000.000.000.000.00
Total Assets20.4842.1378.12110.05163.87206.1535.1537.3773.80
Short Term Debt Incl. Current Port. of LT Debt1.198.891.301.140.682.290.176.885.89
Accounts Payable5.613.023.173.196.424.174.462.915.42
Other Current Liabilities7.277.119.045.686.343.621.913.462.79
Total Current Liabilities14.0819.0313.5210.0113.4410.086.5413.2514.10
Long Term Debt0.4328.2444.0952.2858.1663.6162.4828.6035.67
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.510.860.841.201.561.790.04--
Other Liabilities0.000.000.000.000.000.000.000.010.03
Total Liabilities15.0248.1358.4563.4973.1675.4869.0641.8649.80
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.46-6.0019.6746.5590.71130.67-33.91-4.5023.99
Total Shareholders Equity5.46-6.0019.6746.5590.71130.67-33.91-4.5023.99
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.46-6.0019.6746.5590.71130.67-33.91-4.5023.99
Total Liabilities & Stockholders Equity20.4842.1378.12110.05163.87206.1535.1537.3773.80
Book Value Per Share8.45-14.1366.74192.75395.90571.22-408.05-54.241,461.59
Tangible Book Value Per Share-5.45-35.3036.27155.56356.70531.96-516.13-162.59914.43
Full-Time Employees243449516028283155
Price to Book Ratio0.25-4.332.540.954.815.74-1.67-5.093.77
Return on Assets-24.22-72.17-50.40-41.38-24.56-24.79-88.65-58.61-81.06
Return on Equity--634.71-143.19-82.58-41.05-61.82--334.15-200.22
Return on Invested Capital-128.73-195.11-74.36-57.34-30.52-15.39-112.51-135.14-89.37
Quick Ratio0.491.394.519.209.1117.143.822.114.56
Current Ratio0.491.394.519.209.1117.143.822.114.56

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-21.15-7.58-43.39-47.41-56.67-45.44-29.91-32.14-32.58
Depreciation0.080.170.200.261.390.990.320.120.18
Other Funds (Non Cash)-9.77-21.547.345.957.765.832.807.373.83
Funds from Operations-30.84-28.95-35.85-41.21-47.52-38.62-26.79-24.65-28.56
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.251.75-3.722.78-6.821.001.05-1.56-1.50
Cash from Operating Activities-30.59-27.20-39.56-38.43-54.34-37.62-25.74-26.20-30.07
Capital Expenditures0.000.000.000.00-0.420.00-0.68-0.04-0.09
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.0029.4437.7933.44-47.90-48.37-4.4221.46
Purchase of Investments0.000.00-18.10-70.34-62.00-93.12-53.45-11.46-26.74
Sale Or Maturity of Investments0.000.0047.54108.1395.4445.235.087.0548.20
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources2.502.500.000.000.000.000.000.000.00
Cash from Investing Activities2.502.5029.4437.7933.02-47.90-49.05-4.4621.37
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock24.5915.3512.0214.125.840.30192.210.070.14
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock24.5915.3512.0214.125.840.30192.210.070.14
Proceedsfrom Stock Options24.5915.3512.0214.125.590.00191.430.000.00
Issuance or Reduction of Debt, Net-1.57-5.59-8.59-6.54-4.97-4.47-3.4023.20-6.10
Change in Long Term Debt-1.57-5.59-8.59-6.54-4.97-4.47-3.4023.20-6.10
Issuance of Long Term Debt0.000.000.000.000.000.000.8964.420.00
Reduction of Long Term Debt-1.57-5.59-8.59-6.54-4.97-4.47-4.29-41.21-6.10
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities23.029.773.447.580.87-4.17188.8123.27-5.96
Net Change in Cash-5.07-14.94-6.686.93-20.45-89.69114.03-7.39-14.65
Free Cash Flow-30.59-27.20-39.56-38.43-54.75-37.62-26.42-26.25-30.15
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments5.6215.005.069.0510.1420.28
Short Term Receivables0.000.000.003.242.752.31
Inventories0.000.000.000.000.000.00
Other Current Assets1.111.611.851.611.532.21
Total Current Assets6.7216.616.9213.9114.4224.81
Net Property, Plant & Equipment1.251.611.952.322.673.03
Total Investments and Advances0.000.540.540.540.540.54
Intangible Assets8.988.988.988.988.988.98
Deferred Tax Assets--0.51---
Other Assets2.011.941.571.892.621.96
Total Assets18.9729.6920.4827.6429.2339.33
Short Term Debt Incl. Current Port. of LT Debt1.041.231.198.188.628.54
Accounts Payable5.396.745.614.454.105.10
Other Current Liabilities7.247.007.277.296.666.48
Total Current Liabilities13.6814.9714.0819.9119.3720.12
Long Term Debt0.000.110.4322.4223.8525.82
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.51---
Other Liabilities0.601.900.000.000.000.00
Total Liabilities14.2816.9815.0242.3343.2245.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.7012.715.46-14.69-13.99-6.61
Total Shareholders Equity4.7012.715.46-14.69-13.99-6.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.7012.715.46-14.69-13.99-6.61
Total Liabilities & Stockholders Equity18.9729.6920.4827.6429.2339.33
Book Value Per Share2.416.368.45-23.07-26.12-12.63
Tangible Book Value Per Share-2.201.86-5.45-37.18-42.90-29.80
Full-Time Employees--24---
Price to Book Ratio0.251.722.34-1.44-1.78-3.33
Return on Assets-87.76-61.34-24.22-104.28-97.73-83.14
Return on Equity--693.93----2,951.24
Return on Invested Capital-182.77-188.83328.62-100.00-87.13-55.27
Quick Ratio0.491.110.490.700.741.23
Current Ratio0.491.110.490.700.741.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-8.58-24.2019.36-7.73-8.59-10.62
Depreciation0.010.010.040.030.040.06
Other Funds (Non Cash)-0.3815.08-25.751.291.451.47
Funds from Operations-8.96-9.12-6.36-6.41-7.10-9.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.690.11-0.020.84-0.911.83
Cash from Operating Activities-9.65-9.00-6.37-5.57-8.01-7.25
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.002.500.000.000.00
Cash from Investing Activities0.000.002.500.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.2818.94-0.126.05-0.5810.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.2818.94-0.126.05-0.5810.00
Proceedsfrom Stock Options-0.2818.94-0.126.05-0.5810.00
Issuance or Reduction of Debt, Net0.000.000.00-1.57-1.56-2.46
Change in Long Term Debt0.000.000.00-1.57-1.56-2.46
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-1.57-1.56-2.46
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.2818.94-0.124.48-2.137.54
Net Change in Cash-9.939.94-3.99-1.09-10.140.28
Free Cash Flow-9.65-9.00-6.37-5.57-8.01-7.25

Revenue breakdown

Consolidation, Policy2024: 8.00K 2025: 43.00K
Gross Royalty2024: 10.90M 2025: 9.40M
United States2024: 10.91M 2025: 9.44M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.58%1.0M5.5M353.17K
2026-10-1525.39%0.4M1.7M208.83K
2026-09-3010.37%0.2M1.7M190.58K
2026-09-153.99%0.1M1.7M300.06K
2026-08-319.72%0.2M1.7M277.03K
2026-08-1418.96%0.3M1.7M251.85K
2026-07-318.20%0.1M1.6M175.05K
2026-07-156.63%0.1M1.6M168.31K
2026-06-3011.06%0.2M1.6M156.40K
2026-06-150.84%0.0M1.6M21.67K
2026-05-290.90%0.0M1.6M21.09K
2026-05-150.87%0.0M1.6M20.66K
2026-04-300.68%0.0M1.9M21.00K
2026-04-150.69%0.0M1.9M18.46K
2026-03-310.17%0.0M1.8M27.29K
2026-03-134.95%0.0M0.6M24.99K
2026-02-275.17%0.0M0.6M24.83K
2026-02-134.87%0.0M0.6M24.68K
2026-01-305.04%0.0M0.6M23.17K
2026-01-155.13%0.0M0.6M21.34K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-068-KCurrent report2026-11-02SEC
2026-11-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-18SEC
2026-10-23PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-18SEC
2026-10-198-KCurrent report2026-10-16SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13424B4SEC
2026-08-12EFFECTEffectiveness filing by commission orderSEC
2026-08-10S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-07-308-KCurrent report2026-07-24SEC
2026-07-17DRSSEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-07-018-K/A2026-07-01SEC
2026-07-018-KCurrent report2026-06-25SEC
2026-06-258-KCurrent report2026-06-25SEC
2026-06-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-25SEC
2026-05-22PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-25SEC
2026-05-228-KCurrent report2026-05-19SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-035.49K100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Bleichroeder LP190.22%
Stonepine Capital Management, LLC165.7%
Nantahala Capital Management, LLC99.00%
Cable Car Capital, LP66.70%
CM Management, LLC27.52%
MORGAN STANLEY25.23%
VANGUARD CAPITAL MANAGEMENT LLC17.20%
M28 Capital Management LP14.25%
FLPUTNAM INVESTMENT MANAGEMENT CO12.29%
RENAISSANCE TECHNOLOGIES LLC7.10%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND10.79%
VANGUARD EXTENDED MARKET INDEX FUND4.80%
Fidelity Extended Market Index Fund0.66%
Fidelity Series Total Market Index Fund0.13%
Fidelity Total Market Index Fund0.08%
Fidelity Nasdaq Composite Index Fund0.01%
Guggenheim Active Allocation Fund0.00%

OakChart. CRIS. Cached 15 minutes.